{
    "relation": [
        [
            "",
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED",
            "Adverse Event",
            "Lack of Efficacy",
            "Protocol Violation",
            "Withdrawal by Subject",
            "Unclassified"
        ],
        [
            "Liraglutide 3.0 mg, no Pre-diabetes",
            "0 [1]",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        [
            "Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)",
            "351 [2]",
            "342",
            "9",
            "1",
            "0",
            "1",
            "6",
            "1"
        ],
        [
            "Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)",
            "350 [2]",
            "343",
            "7",
            "1",
            "0",
            "0",
            "4",
            "2"
        ],
        [
            "Liraglutide Placebo, no Pre-diabetes",
            "304 [2]",
            "289",
            "15",
            "2",
            "1",
            "3",
            "7",
            "2"
        ],
        [
            "Liraglutide 3.0 mg, Pre-diabetes",
            "0 [1]",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        [
            "Liraglutide Placebo, Pre-diabetes",
            "0 [1]",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ]
    ],
    "pageTitle": "Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE\u2122 - Obesity and Pre-diabetes - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01272219?view=record",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 6,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988048.90/warc/CC-MAIN-20150728002308-00005-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 870072427,
    "recordOffset": 870055299,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Period 1: \u00a0 Main Period: Week 0 to Week 56 Participant Flow for 2 periods Arm 4: Subjects with pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks, followed by an off-drug, observational follow-up period of 12 weeks. The total duration of this treatment arm from randomisation to follow-up was 172 weeks. Liraglutide Placebo, Pre-diabetes Arm 3: Subjects with pre-diabetes at screening received liraglutide 3.0 mg, once daily (OD) subcutaneously (s.c. injection, under the skin) for initial 56 weeks then continued treatment till 160 weeks, followed by an off-drug, observational follow-up period of 12 weeks. The total duration of this treatment arm from randomisation to follow-up was 172 weeks. Liraglutide 3.0 mg, Pre-diabetes Arm 2: Subjects with no pre-diabetes at screening received liraglutide placebo once daily (OD) subcutaneously (s.c. injection, under the skin) for 56 weeks and then continued with liraglutide placebo for additional 12 weeks (weeks 56-68), followed by a 2 weeks off-drug follow-up period. The total duration of this treatment arm from randomisation to follow-up was 70 weeks. Liraglutide Placebo, no Pre-diabetes Arm 1B: Subjects of Arm 1 (with no pre-diabetes at screening)",
    "textAfterTable": "Unclassified \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 36 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 29 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 42 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 34 \u00a0 [1] This arm is not considered for main period as these subjects belong to re-randomised period Period 2: \u00a0 Re-randomised Period: Week 56 to Week 68 \u00a0 \u00a0 Liraglutide 3.0 mg, no Pre-diabetes \u00a0 \u00a0 Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) \u00a0 \u00a0 Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68) \u00a0 \u00a0 Liraglutide Placebo, no Pre-diabetes \u00a0 \u00a0 Liraglutide 3.0 mg, Pre-diabetes \u00a0 \u00a0 Liraglutide Placebo, Pre-diabetes \u00a0 STARTED \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}